DK0553113T3 - Adhæsionsreceptorer for patogene eller opportunistiske mikroorganismer - Google Patents

Adhæsionsreceptorer for patogene eller opportunistiske mikroorganismer

Info

Publication number
DK0553113T3
DK0553113T3 DK91916508T DK91916508T DK0553113T3 DK 0553113 T3 DK0553113 T3 DK 0553113T3 DK 91916508 T DK91916508 T DK 91916508T DK 91916508 T DK91916508 T DK 91916508T DK 0553113 T3 DK0553113 T3 DK 0553113T3
Authority
DK
Denmark
Prior art keywords
3galb1
galb1
methods
receptors
pathogenic
Prior art date
Application number
DK91916508T
Other languages
Danish (da)
English (en)
Inventor
Howard C Krivan
James E Samuel
Original Assignee
Antex Biolog Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Antex Biolog Inc filed Critical Antex Biolog Inc
Application granted granted Critical
Publication of DK0553113T3 publication Critical patent/DK0553113T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C07H15/10—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical containing unsaturated carbon-to-carbon bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C07H3/06—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Food Science & Technology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK91916508T 1990-08-02 1991-07-29 Adhæsionsreceptorer for patogene eller opportunistiske mikroorganismer DK0553113T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56200290A 1990-08-02 1990-08-02
PCT/US1991/005179 WO1992002817A1 (fr) 1990-08-02 1991-07-29 Recepteurs d'adhesion pour des micro-organismes pathogenes ou opportunistes

Publications (1)

Publication Number Publication Date
DK0553113T3 true DK0553113T3 (da) 1999-08-09

Family

ID=24244391

Family Applications (1)

Application Number Title Priority Date Filing Date
DK91916508T DK0553113T3 (da) 1990-08-02 1991-07-29 Adhæsionsreceptorer for patogene eller opportunistiske mikroorganismer

Country Status (9)

Country Link
US (1) US5696000A (fr)
EP (1) EP0553113B1 (fr)
JP (1) JPH06501383A (fr)
AT (1) ATE173827T1 (fr)
CA (1) CA2095642C (fr)
DE (1) DE69130536T2 (fr)
DK (1) DK0553113T3 (fr)
ES (1) ES2127198T3 (fr)
WO (1) WO1992002817A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5736533A (en) * 1995-06-07 1998-04-07 Neose Technologies, Inc. Bacterial inhibition with an oligosaccharide compound
WO1997018790A2 (fr) * 1995-11-22 1997-05-29 The Research And Development Institute, Inc. Agents therapeutiques et de diagnostic pour traiter les infections microbiennes
CA2213775C (fr) * 1995-12-27 2001-02-27 Ngk Insulators, Ltd. Inhibiteur de metastases cancereuses contenant un polysaccharide de surface de streptococcus agalactiae de type ia ou de type ib comme composant principal
US6207157B1 (en) * 1996-04-23 2001-03-27 The United States Of America As Represented By The Department Of Health And Human Services Conjugate vaccine for nontypeable Haemophilus influenzae
AU6084598A (en) * 1997-02-26 1998-09-18 Hsc Research And Development Limited Partnership Antibiotic-ligand conjugates and methods of use thereof
AU8967998A (en) * 1998-02-25 1999-09-15 Hsc Research & Development Limited Partnership Antibiotic-ligand conjugates and methods of use thereof
AUPQ275799A0 (en) * 1999-09-10 1999-10-07 Luminis Pty Limited Recombinant bacterium expressing an oligosaccharide receptor mimic
GB0001450D0 (en) 2000-01-21 2000-03-08 Genpoint As Cell isolation method
US6869602B2 (en) * 2002-02-20 2005-03-22 The United States Of America As Represented By The Secretary Of The Army Method for treating, preventing, or inhibiting enterotoxigenic Escherichia coli infections with bovine red blood cells
US20030176326A1 (en) * 2002-03-15 2003-09-18 Ceramoptec Industries Inc. Photosensitzers for photodynamic therapy of microbial infections
ATE361101T1 (de) 2004-08-24 2007-05-15 Nutricia Nv Nahrungszusammensetzung die unverdauliche oligosaccharide enthält
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4034074A (en) * 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US4134792A (en) * 1976-12-06 1979-01-16 Miles Laboratories, Inc. Specific binding assay with an enzyme modulator as a labeling substance
US4271140A (en) * 1978-01-23 1981-06-02 Baxter Travenol Laboratories, Inc. Method and composition for double receptor, specific binding assays
US4299916A (en) * 1979-12-26 1981-11-10 Syva Company Preferential signal production on a surface in immunoassays
SE8001748L (sv) * 1980-03-05 1981-09-06 Kaellenius Gunilla Kompositioner for terapeutisk eller diagnostisk anvendning jemte forfarande for terapeutik
US4464360A (en) * 1980-05-09 1984-08-07 Hakon Leffler Glycosphingalipids for inhibiting bacterial adherence
US4376110A (en) * 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4474892A (en) * 1983-02-16 1984-10-02 Board Of Trustees Of The Leland Stanford Junior University Two-site immunoassays using monoclonal antibodies of different classes or subclasses and test kits for performing same
SE8301609D0 (sv) * 1983-03-23 1983-03-23 Svenska Sockerfabriks Ab Forening och komposition for terapeutisk eller diagnostisk anvendning jemte forfarande for terapeutisk behandling
US4762713A (en) * 1983-07-05 1988-08-09 The University Of Rochester Boosting of immunogenic conjugate vaccinations by unconjugated bacterial capsular polymers
DK219084D0 (da) * 1984-05-02 1984-05-02 Frederik Carl Peter Lindberg Antigen
US4610868A (en) * 1984-03-20 1986-09-09 The Liposome Company, Inc. Lipid matrix carriers for use in drug delivery systems
US4762800A (en) * 1984-04-26 1988-08-09 Sloan-Kettering Institute For Cancer Research Monoclonal antibodies to cell surface antigens of human teratocarcinomas
DK17885D0 (da) * 1985-01-14 1985-01-14 Karlsson Karl Anders Antiviralt middel
US4661345A (en) * 1985-02-26 1987-04-28 The Rockefeller University Method for treating pertussis
US4786592A (en) * 1986-06-18 1988-11-22 Scripps Clinic And Research Foundation Neisseria gonorrhoeae lectin useful as a vaccine and diagnostic marker and means for producing this lectin
IT1235011B (it) * 1988-07-26 1992-06-16 Fidia Farmaceutici Sintesi di derivati di glicosfingolipidi ed in particolare di gangliosidi utilizzabili per la preparazione di immunoadsorbenti ed adsorbenti per affinita' impiegabili per la purificazione di anticorpi e di tossine specifiche, e per uso diagnostico
US5225330A (en) * 1988-08-01 1993-07-06 The United States Of America As Represented By The Department Of Health And Human Services Diagnostic kit and diagnostic method utilizing carbohydrate receptors
US5217715A (en) * 1988-08-01 1993-06-08 The United States Of America As Represented By The Department Of Health And Human Services Carbohydrate receptor for bacteria and method for use thereof
US4969540A (en) * 1989-09-28 1990-11-13 Allied-Signal Inc. Center loop anti-rattle spring

Also Published As

Publication number Publication date
US5696000A (en) 1997-12-09
DE69130536T2 (de) 1999-04-22
CA2095642A1 (fr) 1992-02-03
DE69130536D1 (de) 1999-01-07
EP0553113A1 (fr) 1993-08-04
EP0553113A4 (fr) 1994-03-30
WO1992002817A1 (fr) 1992-02-20
ES2127198T3 (es) 1999-04-16
ATE173827T1 (de) 1998-12-15
EP0553113B1 (fr) 1998-11-25
CA2095642C (fr) 1999-12-14
JPH06501383A (ja) 1994-02-17

Similar Documents

Publication Publication Date Title
US5256641A (en) Covalent polar lipid-peptide conjugates for immunological targeting
DK0553113T3 (da) Adhæsionsreceptorer for patogene eller opportunistiske mikroorganismer
LV12766A (lv) Composition of l-dopa esters
OA07711A (fr) Nouveaux conjugués de la vinblastine, leur procédé de préparation et leur utilisation thérapeutique.
FR2442054A1 (fr) Proteines purifiees, notamment interferon, procede de preparation et compositions pharmaceutiques les contenant
US5756449A (en) Peptide T and related peptides in the treatment of inflammation, including inflammatory bowel disease
DK0769020T3 (da) Nye hIL-4-mutantproteiner som antagonister eller delvise agonister for det humane interleukin-4
PT929574E (pt) Moduladores da agregacao de peptidos beta-amiloides compreendendo d-aminoacidos
NZ332311A (en) Use of autoantigen HC gp-39 and proteins structurally related thereto in immunotherapy of autoimmune diseases particularly rheumatoid arthritis
Torres et al. Arginine vasopressin (AVP) replacement of helper cell requirement in IFN-gamma production. Evidence for a novel AVP receptor on mouse lymphocytes.
ATE258933T1 (de) Übergangszustand-analoga des kokains, ihre verwendung zur herstellung von kataltischen antikörpern gegen kokain und verwendung derselben in diagnose und therapie
MX9302327A (es) Aminoacidos ciclicos novedosos y derivados de los mismos.
ATE237343T1 (de) Retropeptide, antikörper dagegen und deren verwendungen in der impfung und in vitro diagnostik
US6011014A (en) Peptide T and related peptides in the treatment of inflammation, including multiple sclerosis
DE69816808D1 (de) Somatostatin agoniste zur reduzierung von körpergewicht
TNSN92115A1 (fr) Succedanes de benzimidazoles, processus de leur preparation ainsi que de leur utilisation
Krueger Somnogenic activity of muramyl peptides
Rees et al. The effect of lipoylation on CD4 T-cell recognition of the 19,000 MW Mycobacterium tuberculosis antigen.
Newell et al. Biochemical characterization of proteins that co-purify with class II antigens of the murine MHC.
DE69923996D1 (de) Methode für die herstellung von gereinigtem invasinprotein und seine anwendung
AU2254999A (en) Use of peptide T in the treatment of multiple sclerosis
DE50011068D1 (de) Fragmente des virus proteins 2 oder 3 des polyomavirus als fähren für wirkstoffe
FR2694938B1 (fr) Nouveaux peptides, anticorps diriges contre ces peptides, anticorps anti-idiotypiques, application a titre de medicaments, compositions pharmaceutiques et kits de diagnostic les renfermant.
RU2130317C1 (ru) Линейные или циклические пептиды, их применение, способ лечения
Brown et al. Extension of a minimal T cell determinant allows relaxation of the requirement for particular residues within the determinant